166 related articles for article (PubMed ID: 17492272)
1. Acute hormonal changes after IV citalopram and treatment response in OCD.
Corregiari FM; Gattaz WF; Bernik M
Psychopharmacology (Berl); 2007 Sep; 193(4):487-94. PubMed ID: 17492272
[TBL] [Abstract][Full Text] [Related]
2. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences.
Lotrich FE; Bies R; Muldoon MF; Manuck SB; Smith GS; Pollock BG
Psychopharmacology (Berl); 2005 Mar; 178(2-3):268-75. PubMed ID: 15365685
[TBL] [Abstract][Full Text] [Related]
3. Endophenotypes and serotonergic polymorphisms associated with treatment response in obsessive-compulsive disorder.
Corregiari FM; Bernik M; Cordeiro Q; Vallada H
Clinics (Sao Paulo); 2012; 67(4):335-40. PubMed ID: 22522758
[TBL] [Abstract][Full Text] [Related]
4. L-5-Hydroxytryptophan augments the neuroendocrine response to a SSRI.
Lowe SL; Yeo KP; Teng L; Soon DK; Pan A; Wise SD; Peck RW
Psychoneuroendocrinology; 2006 May; 31(4):473-84. PubMed ID: 16378695
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine predictors of response to intravenous clomipramine therapy for refractory obsessive-compulsive disorder.
Mathew SJ; Coplan JD; Perko KA; Goetz RR; de la Neuz M; Hollander E; Liebowitz MR; Fallon BA
Depress Anxiety; 2001; 14(4):199-208. PubMed ID: 11754126
[TBL] [Abstract][Full Text] [Related]
6. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial.
Pallanti S; Quercioli L; Koran LM
J Clin Psychiatry; 2002 Sep; 63(9):796-801. PubMed ID: 12363120
[TBL] [Abstract][Full Text] [Related]
7. Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopram.
Carey PD; Warwick J; Niehaus DJ; van der Linden G; van Heerden BB; Harvey BH; Seedat S; Stein DJ
BMC Psychiatry; 2004 Oct; 4():30. PubMed ID: 15482603
[TBL] [Abstract][Full Text] [Related]
8. Brain neurochemistry in unmedicated obsessive-compulsive disorder patients and effects of 12-week escitalopram treatment:
Parmar A; Sharan P; Khandelwal SK; Agarwal K; Sharma U; Jagannathan NR
Psychiatry Clin Neurosci; 2019 Jul; 73(7):386-393. PubMed ID: 30973183
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the effects of citalopram and escitalopram on 5-Ht-mediated neuroendocrine responses.
Nadeem HS; Attenburrow MJ; Cowen PJ
Neuropsychopharmacology; 2004 Sep; 29(9):1699-703. PubMed ID: 15127082
[TBL] [Abstract][Full Text] [Related]
10. Prolactin and cortisol responses to MK-212, a serotonin agonist, in obsessive-compulsive disorder.
Bastani B; Nash JF; Meltzer HY
Arch Gen Psychiatry; 1990 Sep; 47(9):833-9. PubMed ID: 2203327
[TBL] [Abstract][Full Text] [Related]
11. The citalopram challenge test in patients with major depression and in healthy controls.
Kapitany T; Schindl M; Schindler SD; Hesselmann B; Füreder T; Barnas C; Sieghart W; Kasper S
Psychiatry Res; 1999 Nov; 88(2):75-88. PubMed ID: 10622344
[TBL] [Abstract][Full Text] [Related]
12. Fluoxetine, but not tricyclic antidepressants, potentiates the 5-hydroxytryptophan-mediated increase in plasma cortisol and prolactin secretion in subjects with major depression or with obsessive compulsive disorder.
Meltzer H; Bastani B; Jayathilake K; Maes M
Neuropsychopharmacology; 1997 Jul; 17(1):1-11. PubMed ID: 9194044
[TBL] [Abstract][Full Text] [Related]
13. Acute citalopram administration produces correlated increases in plasma and salivary cortisol.
Bhagwagar Z; Hafizi S; Cowen PJ
Psychopharmacology (Berl); 2002 Aug; 163(1):118-20. PubMed ID: 12185409
[TBL] [Abstract][Full Text] [Related]
14. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD).
Pogarell O; Poepperl G; Mulert C; Hamann C; Sadowsky N; Riedel M; Moeller HJ; Hegerl U; Tatsch K
Eur Neuropsychopharmacol; 2005 Oct; 15(5):521-4. PubMed ID: 16139170
[TBL] [Abstract][Full Text] [Related]
15. Neuroendocrine effects of citalopram infusion in anorexia nervosa.
Mondelli V; Gianotti L; Picu A; Abbate Daga G; Giordano R; Berardelli R; Pariante CM; Fassino S; Ghigo E; Arvat E
Psychoneuroendocrinology; 2006 Nov; 31(10):1139-48. PubMed ID: 17045409
[TBL] [Abstract][Full Text] [Related]
16. Use of the selective serotonin reuptake inhibitor citalopram in a possible animal analogue of obsessive-compulsive disorder.
Stein DJ; Mendelsohn I; Potocnik F; Van Kradenberg J; Wessels C
Depress Anxiety; 1998; 8(1):39-42. PubMed ID: 9750979
[TBL] [Abstract][Full Text] [Related]
17. Effect of sleep deprivation on neuroendocrine response to a serotonergic probe in healthy male subjects.
Seifritz E; Müller MJ; Annen O; Nil R; Hatzinger M; Hemmeter U; Moore P; Holsboer-Trachsler E
J Psychiatr Res; 1997; 31(5):543-54. PubMed ID: 9368196
[TBL] [Abstract][Full Text] [Related]
18. Predictors of response to pharmacotherapy with citalopram in obsessive-compulsive disorder.
Stein DJ; Montgomery SA; Kasper S; Tanghoj P
Int Clin Psychopharmacol; 2001 Nov; 16(6):357-61. PubMed ID: 11712625
[TBL] [Abstract][Full Text] [Related]
19. The effects of an acute serotonergic challenge on brain-gut responses in irritable bowel syndrome patients and controls.
Kilkens TO; Honig A; Fekkes D; Brummer RJ
Aliment Pharmacol Ther; 2005 Nov; 22(9):865-74. PubMed ID: 16225497
[TBL] [Abstract][Full Text] [Related]
20. Beyond depression: citalopram for obsessive-compulsive disorder.
Pato MT
Int Clin Psychopharmacol; 1999 May; 14 Suppl 2():S19-26. PubMed ID: 10471169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
